Amy E. McKee

3.9k citations

37 papers · 2.3k indexed · h-index 24

Impact in

Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Research Studies
Cancer Research top 5%
- Cancer Genomics and Diagnostics

Papers in ⓘ

Oncology 17
- Cancer Immunotherapy and Biomarkers 5
Statistics and Probability 5
- Statistical Methods in Clinical Trials 5

Co-authors: Richard Pazdur (26 shared papers)Kirsten B. Goldberg (13 shared papers)Gideon M. Blumenthal (8 shared papers)Carol J. Thiele (4 shared papers)Patricia Keegan (10 shared papers)Zhijie Li (1 shared paper)Kun He (5 shared papers)Sriram Subramaniam (5 shared papers)
Journals: The Oncologist (14 papers)Clinical Cancer Research (8 papers)Journal of Clinical Oncology (3 papers)Cancer (1 paper)Expert Opinion on Therapeutic Targets (1 paper)
Partner nations: United States Canada France

In The Last Decade

Amy E. McKee

37 papers receiving 2.2k citations

Peers

Countries citing papers authored by Amy E. McKee

Since Specialization

Citations

This map shows the geographic impact of Amy E. McKee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy E. McKee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy E. McKee more than expected).

Fields of papers citing papers by Amy E. McKee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy E. McKee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy E. McKee. The network helps show where Amy E. McKee may publish in the future.

Co-authors

The 25 scholars most cited alongside Amy E. McKee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Amy E. McKee Line = papers co-authored together Amy E. McKee links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond The Oncologist ·Lee H. Pai-Scherf, Gideon M. Blumenthal, Hongshan Li, Sriram Subramaniam, Pallavi S. Mishra‐Kalyani, Kun He, Hong Zhao, Jingyu Yu, Mark Paciga, Kirsten B. Goldberg, Amy E. McKee, Patricia Keegan, Richard Pazdur	2017	228
2	FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma Clinical Cancer Research ·Najat Bouchkouj, Yvette L. Kasamon, R. Angelo de Claro, Bindu George, Xue Lin, Shiowjen Lee, Gideon M. Blumenthal, Wilson W. Bryan, Amy E. McKee, Richard Pazdur	2018	190
3	OnTrk—The TrkB Signal Transduction Pathway Is an Increasingly Important Target in Cancer Biology Clinical Cancer Research ·Carol J. Thiele, Zhijie Li, Amy E. McKee	2009	187
4	FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy The Oncologist ·Erin Larkins, Gideon M. Blumenthal, Weishi Yuan, Kun He, Rajeshwari Sridhara, Sriram Subramaniam, Hong Zhao, Chao Liu, Jingyu Yu, Kirsten B. Goldberg, Amy E. McKee, Patricia Keegan, Richard Pazdur	2017	172
5	FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1 The Oncologist ·Lola A. Fashoyin‐Aje, Martha Donoghue, Huanyu Chen, Kun He, Janaki Veeraraghavan, Kirsten B. Goldberg, Patricia Keegan, Amy E. McKee, Richard Pazdur	2018	171
6	FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations The Oncologist ·Lauretta Odogwu, Luckson Mathieu, Gideon M. Blumenthal, Erin Larkins, Kirsten B. Goldberg, Norma Sue Griffin, Karen E. Bijwaard, Eunice Lee, Reena Philip, Xiaoping Jiang, Lisa Rodríguez, Amy E. McKee, Patricia Keegan, Richard Pazdur	2018	166
7	FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy The Oncologist ·Daniel L. Suzman, Sundeep Agrawal, Yang-Min Ning, V. Ellen Maher, Laura L. Fernandes, Stella Karuri, Shenghui Tang, Rajeshwari Sridhara, Jason Schroeder, Kirsten B. Goldberg, Amna Ibrahim, Amy E. McKee, Richard Pazdur, Julia A. Beaver	2018	138
8	Neuroblastoma Cells Isolated from Bone Marrow Metastases Contain a Naturally Enriched Tumor-Initiating Cell Cancer Research ·Loen M. Hansford, Amy E. McKee, Libo Zhang, Rani E. George, J. Ted Gerstle, Paul S. Thorner, Kristen M. Smith, A. Thomas Look, Herman Yeger, Freda D. Miller, Meredith S. Irwin, Carol J. Thiele, David R. Kaplan	2007	132
9	FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Clinical Cancer Research ·Amanda J. Walker, Suparna Wedam, Laleh Amiri‐Kordestani, Erik Bloomquist, Shengui Tang, Rajeshwari Sridhara, Wei Chen, Todd R. Palmby, Jeanne Fourie Zirkelbach, Wentao Fu, Qi Liu, Amy Tilley, Geoffrey Kim, Paul G. Kluetz, Amy E. McKee, Richard Pazdur	2016	104
10	FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non–Small Cell Lung Cancer Following Crizotinib Clinical Cancer Research ·Erin Larkins, Gideon M. Blumenthal, Huanyu Chen, Kun He, Rajiv Agarwal, Gerlie Gieser, Olen Stephens, Eias Zahalka, Kimberly Ringgold, Whitney S. Helms, Stacy S. Shord, Jingyu Yu, Hong Zhao, Gina Davis, Amy E. McKee, Patricia Keegan, Richard Pazdur	2016	88
11	The Role of the U.S. Food and Drug Administration Review Process: Clinical Trial Endpoints in Oncology The Oncologist ·Amy E. McKee, Ann T. Farrell, Richard Pazdur, Janet Woodcock	2010	61
12	FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy The Oncologist ·Vishal Bhatnagar, Nicole Gormley, Lola Luo, Yuan Li Shen, Rajeshwari Sridhara, Sriram Subramaniam, Guoxiang Shen, Lian Ma, Stacy S. Shord, Kirsten B. Goldberg, Ann T. Farrell, Amy E. McKee, Richard Pazdur	2017	58
13	Successes and Challenges of PARP Inhibitors in Cancer Therapy Frontiers in Oncology ·Tiffany K. Ricks, Haw-Jyh Chiu, Gwynn Ison, Geoffrey Kim, Amy E. McKee, Paul G. Kluetz, Richard Pazdur	2015	57
14	FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation The Oncologist ·Patricia O’Neal, Virginia E. Kwitkowski, Lola Luo, Yuan Li Shen, Sriram Subramaniam, Stacy S. Shord, Kirsten B. Goldberg, Amy E. McKee, Edvardas Kaminskas, Ann T. Farrell, Richard Pazdur	2018	53
15	Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies The Oncologist ·Gideon M. Blumenthal, Paul G. Kluetz, Julie A. Schneider, Kirsten B. Goldberg, Amy E. McKee, Richard Pazdur	2017	48
16	FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia The Oncologist ·Dianne Pulte, Jonathon Vallejo, Donna Przepiorka, Lei Nie, Ann T. Farrell, Kirsten B. Goldberg, Amy E. McKee, Richard Pazdur	2018	44
17	FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma Clinical Cancer Research ·Julia A. Beaver, Marc R. Theoret, Sirisha L. Mushti, Kun He, Meredith Libeg, Kirsten B. Goldberg, Rajeshwari Sridhara, Amy E. McKee, Patricia Keegan, Richard Pazdur	2017	42
18	FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis The Oncologist ·Yvette L. Kasamon, Chia‐Wen Ko, Sriram Subramaniam, Lian Ma, Yuching Yang, Lei Nie, Stacy S. Shord, Donna Przepiorka, Ann T. Farrell, Amy E. McKee, Richard Pazdur	2018	33
19	FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma The Oncologist ·Elizabeth Pulte, Andrew Dmytrijuk, Lei Nie, Kirsten B. Goldberg, Amy E. McKee, Ann T. Farrell, Richard Pazdur	2018	32
20	The FDA Oncology Center of Excellence and precision medicine Experimental Biology and Medicine ·Kirsten B. Goldberg, Gideon M. Blumenthal, Amy E. McKee, Richard Pazdur	2017	28

About Amy E. McKee

Amy E. McKee is a scholar working on Oncology, Statistics and Probability, Cancer Research, Hematology and Immunology, having authored 37 papers that have together received 2.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (8 papers), Cancer Genomics and Diagnostics (7 papers), Cancer Immunotherapy and Biomarkers (5 papers), Statistical Methods in Clinical Trials (5 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers), Neuroblastoma Research and Treatments (4 papers), Biosimilars and Bioanalytical Methods (4 papers) and Economic and Financial Impacts of Cancer (3 papers). The work is most often cited by research in Oncology (1.3k citations), Cancer Research (339 citations), Pulmonary and Respiratory Medicine (605 citations), Immunology (370 citations) and Neurology (195 citations). Amy E. McKee has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Richard Pazdur, Kirsten B. Goldberg, Gideon M. Blumenthal, Carol J. Thiele, Patricia Keegan, Zhijie Li, Kun He, Sriram Subramaniam, Rajeshwari Sridhara and Ann T. Farrell. Their work appears in journals such as The Oncologist, Clinical Cancer Research, Journal of Clinical Oncology, Cancer and Expert Opinion on Therapeutic Targets.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact